Innocan Pharma Engages Lytham Partners to Lead Investor Relations and Shareholder Communication Program
Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - May 10, 2021) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") today announced it has retained Lytham Partners, LLC ("Lytham Partners") to lead an investor relations and shareholder communication program.
For more than 20 years, Lytham Partners has been one of the industry's leading investor relations firms, having created one of the largest and most diverse networks of institutional investors, while creating a framework of best practices in all aspects of corporate and shareholder communications. Lytham Partners works with many NASDAQ listed companies in order to properly and effectively communicate their value to the institutional investment community.
Iris Bincovich, Chief Executive of Innocan Pharma commented, "We have made significant progress since becoming a publicly traded company in September 2019. Our proprietary and differentiated research projects continue to deliver highly innovative treatments and provide strong returns on investment. The United States is an integral geography as it relates to our scientific projects, and we believe the timing is appropriate to expand our awareness within the U.S. investment community. We look forward to working with the team at Lytham Partners, which has a strong understanding of both Pharmaceutical & Cannabis space, to further assist us in these efforts."
Ben Shamsian, Vice President of Lytham Partners, said, "Given Innocan Pharma's robust scientific advancement profile, we believe the U.S. investment community will be interested to learn more about their unique value proposition and opportunities ahead to create value for shareholders. We look forward to introducing the Company to our platform of investors, while installing best practices within their communications program at all levels to keep shareholders apprised of the developments taking place at the Company."
In connection with the engagement, Lytham Partners will be compensated USD $6,500 per month.
The Company, through its wholly owned Israeli subsidiary, Innocan Pharma Ltd. ("Innocan Israel"), is a pharmaceutical tech company that focuses on the development of several drug delivery platforms combining cannabidiol ("CBD"). Innocan Israel and Ramot at Tel Aviv University are collaborating on a new, revolutionary exosome-based technology that targets both central nervous system (CNS) indications and the Covid-19 Coronavirus using CBD. CBD-loaded exosomes hold the potential to help in the recovery of infected lung cells. This product, which is expected to be administrated by inhalation, will be tested against a variety of lung infections.
Innocan Israel signed a worldwide exclusive license agreement with Yissum, the commercial arm of the Hebrew University of Jerusalem to develop a CBD drug delivery platform based on a unique-controlled release liposome to be administrated by injection. Innocan Israel plans, together with Professor Berenholtz, Head of the Laboratory of Membrane and Liposome Research of the Hebrew University, to test the liposome platform on several potential indications. Innocan Israel is also working on a dermal product that integrates CBD with other pharmaceutical ingredients as well as the development and sale of CBD-integrated pharmaceuticals, including, but not limited to, topical treatments for relief of psoriasis symptoms as well as the treatment of muscle pain and rheumatic pain. The founders and officers of Innocan have commercially successful track records in the pharmaceutical and technology sectors in Israel and globally.
For further information, please contact:
For Innocan Pharma Corporation:
Iris Bincovich, CEO
Lytham Partners, LLC
New York | Phoenix
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
Caution regarding forward-looking information
Certain information and statements set forth in this news release, including, without limitation, information regarding the markets, requisite regulatory approvals and the anticipated timing for market entry, are forward-looking information and forward-looking statements within the meaning of applicable securities laws (collectively "forward-looking information"). By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan's control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of trading on the OTCQB Venture Market and DTC eligibility including increased liquidity and broadening our shareholder base, and building a strong presence for our company within US capital markets, the benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of requisite production and distribution arrangements.
Forward-looking information is subject to various risks and uncertainties which could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: general global and local (national) economic, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and relationships with suppliers, manufacturers, customers, business partners and competitors and that liquidity for our common shares and that our shareholder base will not increase. There are also risks that are inherent in the nature of product distribution, including import / export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner) and availability in each market of product inputs and finished products. The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release concerning the timing of launch of product distribution. A comprehensive discussion of other risks that impact Innocan can also be found in Innocan's public reports and filings which are available under Innocan's profile at www.sedar.com.
Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/83474